Accession Number:

ADA609928

Title:

Inhibition of the Androgen Receptor Amino-Terminal Domain by a Small Molecule as Treatment for Castrate-Resistant Prostate Cancer

Descriptive Note:

Annual rept. 15 Sep 2013-14 Sep 2014

Corporate Author:

WASHINGTON UNIV SEATTLE

Personal Author(s):

Report Date:

2014-10-01

Pagination or Media Count:

7.0

Abstract:

During the past year data has been published from our group as well as others that the AR- splice variants are at least markers of resistance to enzalutamide and abiraterone when found in circulating tumor cells and are harbingers of a more lethal disease. Thus the need to develop and understand the mechanisms of action of EPI-compounds on the constitutively active AR spice variants is urgent. Furthermore, in this years report we will show new information on the mechanism of action of EPI compounds and how they effect AR-V interaction with chromatin. Finally, we will show the significance of newly developed specific AR-V antibodies and how they will be used to further dissect the mechanisms of action of the EPI compounds.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE